Dollar Retreat Boosts Gold Prices as Market Weighs Federal Reserve Rate Hike Path
智通财经2026/10/08 02:411. On Thursday, as the US dollar retreated from its 18-month high, gold prices rebounded from a two-month low. As of 10:25, spot gold rose as much as 0.74% to $4140.08 per ounce. The weaker dollar reduced the purchase cost of gold for buyers using other currencies, thereby supporting gold prices. On Wednesday, gold prices had touched their lowest level since August 5 due to a stronger dollar and rising US Treasury yields. In the Asian session on Thursday, the US dollar index edged down by 0.1%, trading near 102.16. 2. Chris Weston, head of research at Pepperstone, stated that the short-term outlook for gold remains rather bearish and it is still a seller’s market. Gold prices need to break above $4275 for a more optimistic near-term outlook. He pointed out that if the market starts viewing the rise in long-term yields as a reflection of sovereign credit and fiscal risks rather than a signal of strong economic performance, gold might start moving in tandem with bond yields, and currency devaluation trades could heat up again. 3. Minutes from the Federal Reserve's September meeting showed that policymakers were divided on the need for a rate hike. Some participants argued that a rate increase was necessary to offset the effects of energy and other price shocks; more hawkish core members advocated for a hike to guard against newly emerging demand-driven inflation. According to the CME FedWatch tool, traders assign only an 18% probability of a rate hike later this month, but expect the probability of a December hike to be as high as 80%. Rising interest rates usually dampen the appeal of non-yielding gold. 4. IMF President Kristalina Georgieva warned that the global economy is under threat from persistently high energy prices, record levels of public debt, and risks from an artificial intelligence investment boom, and urged governments to adopt protective fiscal and monetary policy measures.
- On Thursday, as the US dollar retreated from an 18-month high, gold prices rebounded from a two-month low. As of 10:25, spot gold once rose 0.74% to $4,140.08 per ounce. The weaker dollar reduced gold purchase costs for buyers using other currencies, providing support for gold prices. On Wednesday, influenced by the stronger dollar and rising US Treasury yields, gold prices had touched their lowest since August 5. During Asian trading on Thursday, the US dollar index edged down, currently falling 0.1% to trade near 102.16.
- Chris Weston, Head of Research at Pepperstone, stated that the short-term outlook for gold remains challenging and it is still a seller's market. Gold prices need to break through $4,275 before a more optimistic view on the recent upward trend can be expected. He mentioned that if the market starts to interpret the rise in long-term yields as a reflection of sovereign credit and fiscal risks, rather than a sign of economic strength, gold may start to move in tandem with bond yields, and currency depreciation trades may regain popularity.
- Minutes from the US Federal Reserve's September meeting show that policymakers were divided on the reasons for raising rates at that time. Some participants believed it was necessary to raise rates to counter the impact of energy and other price shocks. More hawkish core members advocated hikes to prevent emerging demand-driven inflation. CME Group's FedWatch tool indicates that traders see only an 18% chance of a rate hike later this month, but the probability for a rate hike in December is as high as 80%. Rising interest rates typically diminish the attractiveness of non-yielding gold.
- Kristalina Georgieva, Managing Director of the International Monetary Fund, warned that the global economy is being threatened by sustained high energy prices, record levels of public debt, and risks stemming from the artificial intelligence investment boom. She urged governments to adopt protective fiscal and monetary policy measures.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ-Applied Digital shares surge as Q1 revenue quadruples
October 8 - ** Data center service provider Applied Digital (APLD.O) saw its stock rise 3.57% in pre-market trading to $24.66 ** The company’s Q1 revenue (link) surged more than fourfold to $341.9 millions, far surpassing analyst estimates of $133.8 millions ** Northland Capital Securities noted that APLD’s revenue and cash flow should increase significantly in the coming years as contracted data center capacity becomes operational and starts generating income ** Net loss attributable to common shareholders widened from $18.5 millions (7 cents/share) a year ago to $221 millions (76 cents/share) ** According to data compiled by London Stock Exchange Group (LSEG), the average rating from 17 analysts covering the stock is “Buy”, with a median target price of $70.00, representing an upside of about 194% from the current price ** Year-to-date, the stock is down about 2.9%, while the Nasdaq Index .IXIC is up 18.5% over the same period. (For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. Since automated translation may contain errors or lack necessary context, Reuters does not guarantee the accuracy of automated translation and provides it only as a convenience. Reuters assumes no liability for any damage or loss resulting from the use of automated translation.)
WTI crude oil rises above $91 per barrel, up 3.02% intraday
WTI crude oil rose above $91 per barrel for the first time since October 2, with a daily increase of 3.02%.
AstraZeneca (AZN.US) and Daiichi Sankyo (DSNKY.US) TROP2 ADC receives approval for new indication in China
According to information from Zhihu Finance APP, AstraZeneca (AZN.US) and Daiichi Sankyo (DSNKY.US) have announced that Datroway® (generic name: datopotamab deruxtecan for injection) has been approved by the National Medical Products Administration (NMPA) of China for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not suitable for PD-1/PD-L1 inhibitor therapies. Datopotamab deruxtecan is an antibody-drug conjugate (ADC) targeting TROP2, developed with proprietary technology by Daiichi Sankyo, and jointly developed and commercialized by AstraZeneca and Daiichi Sankyo.
Abu Dhabi National Oil Company invites bids for crude oil cargo shipments
Trader: Abu Dhabi National Oil Company issued a tender this week to sell crude oil for December loading or January delivery.
Crypto prices
More
